Moreover, low levels of Mfn-2 expression correlate with a poorer prognosis in breast cancer patients and low Mfn-1 is associated with an increased metastatic capacity in hepatocellular carcinoma (HCC) [65]. Here, MFN2 is linked to hepatocellular carcinoma.